SCHEMBL1716296

SCHEMBL1716296

N#CCc1ccccc1CBr

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
CYP1A1 P04798 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP1B1 Q16678 2/20 0.43
TRPA1 O75762 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
CSNK2A1 P68400 2/20 0.34
FFAR1 O14842 3/20 0.34
FFAR4 Q5NUL3 1/20 0.34
ATP4A P20648 1/20 0.33
ATP4B P51164 1/20 0.33
KDM4E B2RXH2 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
LMNA P02545 1/20 0.32
EGFR P00533 1/20 0.32
SRC P12931 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30739092 1.00 ALDH1A1 (0.47) ALDH1A1HPGDCYP1A1CYP1A2CYP1B1
SCHEMBL1945874 0.87 ALDH1A1 (0.56) ALDH1A1HPGDCYP1A1CYP1A2CYP1B1
SCHEMBL29809738 0.87 ALDH1A1 (0.56) ALDH1A1HPGDCYP1A1CYP1A2CYP1B1
SCHEMBL27783461 0.82 ALDH1A1 (0.44) ALDH1A1HPGDCYP1A1CYP1A2CYP1B1
SCHEMBL8763318 0.80 ALDH1A1 (0.50) ALDH1A1HPGDCYP1A1CYP1A2CYP1B1
SCHEMBL29382225 0.79 TSHR (0.50) ALDH1A1CYP1A1CYP1A2CYP1B1TRPA1
SCHEMBL28289 0.79 TSHR (0.50) ALDH1A1CYP1A1CYP1A2CYP1B1TRPA1
SCHEMBL24176025 0.76 ALDH1A1 (0.47) ALDH1A1HPGDCYP1A1CYP1A2CYP1B1
SCHEMBL3917506 0.76 ALDH1A1 (0.47) ALDH1A1HPGDCYP1A1CYP1A2CYP1B1
SCHEMBL860437 0.76 ALDH1A1 (0.47) ALDH1A1HPGDCYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198274-B2 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2012-06-12 US disclosed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC 2010-01-21 US disclosed
WO-2010006945-A1 SUBSTITUTED INDOLYL AND INDAZOLYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2010-01-21 WO disclosed
CN-101531631-A Substituted pyridinones as modulators of p38 map kinase PHARMACIA CORP (US) 2009-09-16 CN disclosed
CN-100486576-C Substituted pyridones as modulators of P38MAP kinase PHARMACIA CORP (US) 2009-05-13 CN disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
EP-0393534-B1 Pharmaceutically active pteridine derivatives ROEHM GMBH (DE) 1995-07-12 EP disclosed
US-5225414-A SUBSTITUTED AZOLES, A PROCESS FOR THEIR PREPARATION, AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1993-07-06 US disclosed
US-5124326-A Antiarrhythmic, hypotensive agents; diuretics ROEHM GMBH CHEMISCHE FABRIK (DE) 1992-06-23 US disclosed
EP-0468372-A2 Substituted azoles, process for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1992-01-29 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
EP-0393534-A2 Pharmaceutically active pteridine derivatives RÖHM GMBH (DE) 1990-10-24 EP disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
WO-1989004305-A1 QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-05-18 WO disclosed
EP-0315399-A2 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1989-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 ALDH1A1 804/4885HPGD 301/4885CYP1A1 2694/4885
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof MAOB, MAOA, TPH1 ALDH1A1 751/4885HPGD 1042/4885CYP1A1 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.